Haichang, at its own expense, will develop its updated RX-0201 through proof-of-concept in China.
February 8, 2018 -- Zhejiang Haichang Biotech will take over development of a targeted liver cancer treatment from Rexahn Pharma of Maryland. Haichang will develop a nano-liposomal formulation of RX-0201 using its QTsome™ technology, which is designed to improve cellular uptake of large molecules and target specific organs. Rexahn will stop US clinical trials of RX-0201 (which is in the middle of a Phase II test) because new liver cancer drugs, approved in the last few years, are more effective. Haichang, at its own expense, will develop its updated RX-0201 through proof-of-concept in China.
